FibroGen (NASDAQ: FGEN) reported Q4 EPS of $0.18, $0.35 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $22.09 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.